More information: Sergio Escamilla et al, Synaptic and extrasynaptic distribution of NMDA receptors in the cortex of Alzheimer's disease patients, Alzheimer's & Dementia (2024). DOI: 10.1002/alz.14125 ...

submission for AXS-05 in Alzheimer’s disease agitation. AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 ...

Another class of medication helps with the symptoms of Alzheimer’s disease. Memantine is an N-methyl D-aspartate (NMDA) antagonist sold under the brand name Namenda. It is used to treat middle ...

Common neurodegenerative changes in glaucoma and Alzheimer's disease. Retinal amyloid-β ... Acetylcholinesterase inhibitors and NMDA receptor modulators may have a neuroprotective role in ...

Neurons generated from stem cells (from skin fibroblasts) of a patient with sporadic Alzheimer’s disease. Visualized with a specific green fluorescent marker. Nuclei are shown in blue.

Axsome Therapeutics (AXSM) has received formal pre-New Drug Application meeting minutes from the U.S. Food and Drug Administration supporting a ...

Due, in part, to the logical nature of the approach, combination therapy is already widely used in clinical practice. Although compounds with a combined cholinergic–glutamatergic action have ...

Based on the feedback from the FDA, the Company’s regulatory data package would be sufficient for the submission of an sNDA for AXS-05 for the treatment of Alzheimer’s disease agitation. Axsome ...